Medicare Risk-Sharing Contracts: A More Feasible Drug Cost Solution?
Duke’s Mark McClellan made a strong pitch for such contracting during a Capitol Hill debate on cost control with Johns Hopkins’ Gerard Anderson.
You may also be interested in...
‘Episode of care’ payment model could reduce off-label cancer drug prescribing but also offers an opportunity for increased use of high-value drugs, including those that can reduce costs by decreasing hospitalizations, University of Chicago’s Rena Conti suggests.
Lilly USA Deputy General Counsel Weems and former Anthem Chief Medical Officer Nussbaum offer insights on how guidance from the HHS Inspector General might help advance value-based contracting.
Performance-based reimbursement agreements with US payers, like the deals that Novartis AG recently struck with Cigna Corp. and Aetna Inc. for the heart failure drug Entresto (sacubitril/valsartan), are rare, but Novartis US Head Christi Shaw said she's hopeful that the concept will catch on.